Clinical Trial Search

Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score

Primary: Change in Action Research Arm Test (ARAT) Score — 6.2 units on a scale — p=0.002

Primary: The Change in Total Daily Energy Expenditure — -0.52; 32.86 change in kcal/day

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Percent Change From Baseline in Jebsen Taylor Hand Function Test Scores — -23.0; 0 percentage of change from baseline

Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743

Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896

Primary: Box and Blocks Test — 0.0; 0.5 Number of blocks moved — p=<0.005

Primary: Percent Change in Box and Block Test — 20 percent change of number of blocks — p=.04

Primary: Changes in the H-reflex Amplitude in Response to Nerve Stimulation

Primary: Total Stroke Specific Quality of Life — 3.80; 3.82; 4.01; 3.94 units on a scale — p=0.0500

Primary: Change in Cognition as Assessed by the Montreal Cognitive Assessment Score — 23.5; 22.5; 25.5; 23.7 score on a scale

Primary: Wolf Motor Function Test (Time) — 10.21; 29.69; 19.09; 26.05 units on a scale — p=<0.05

Primary: Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) — -3.66; -0.51; -4.00; -3.89 Seconds

Primary: Rate and Severity of Falls (Calculated With an Algorithm) — 2; 2 score on a scale

Primary: Arm Motor Abilities Test Functional Domain (AMAT - F) — .54 units on a scale

Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV

Primary: Quality of Motor Performance — .49; .67 percentage of samples not 'on' task

Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs

Primary: Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs) — 30…

Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients

Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Change From Baseline in Upper Limb Fugl Meyer Score — 7.0; 7.7 Units on a scale

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 6; 8; 6 Participants

Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011

Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale

Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees